Dogwood Therapeutics Inc (DWTX) Stock Price, Quote & News

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States

HeyHoser Dec. 29 at 8:18 PM

$IBRX and $DWTX ... nice EOY

0 · Reply

Drainomight Dec. 29 at 6:40 PM

$DWTX

0 · Reply

BillionerOfKing Dec. 25 at 6:29 PM

$DWTX Current Stock Price: $4.36

0 · Reply

GrapeGains Dec. 25 at 9:38 AM

$DWTX Capital discipline has become the critical gating factor, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.

0 · Reply

Fkubini2442 Dec. 23 at 7:42 PM

$DWTX

0 · Reply

HeyHoser Dec. 23 at 7:15 PM

$DWTX wow, nice EOY buy opp.

0 · Reply

hammerfall43 Dec. 23 at 5:18 PM

$DWTX 2$

1 · Reply

UgoGreg Dec. 22 at 7:48 PM

$DWTX https://youtu.be/Pga-Rf9NLOY

0 · Reply

mikesterz7 Dec. 22 at 6:13 PM

$DWTX The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement.

1 · Reply

StocktwitsNews Dec. 22 at 6:05 PM

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence $DWTX $VXF https://stocktwits.com/news/equity/markets/dogwood-therapeutics-interim-trial-results-in-chemotherapy-induced-pain-fail-to-boost-investor-confidence/cLeF8WPREMu

0 · Reply

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dec 2, 2025, 8:00 AM EST - 4 weeks ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Nov 11, 2025, 8:45 AM EST - 7 weeks ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 6, 2025, 8:45 AM EST - 7 weeks ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:15 AM EDT - 2 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 14, 2025, 8:45 AM EDT - 2 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 7, 2025, 8:45 AM EDT - 3 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Sep 29, 2025, 12:17 PM EDT - 3 months ago

Dogwood Therapeutics, Inc. - Special Call

Sep 29, 2025, 7:15 AM EDT - 3 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 3, 2025, 9:15 AM EDT - 4 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 9:00 AM EDT - 5 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 1:08 PM EDT - 5 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 6, 2025, 9:15 AM EDT - 5 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jun 3, 2025, 9:15 AM EDT - 7 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

May 8, 2025, 9:00 AM EDT - 8 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 1, 2025, 8:30 AM EDT - 8 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 11, 2025, 9:15 AM EDT - 9 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 3, 2025, 9:00 AM EDT - 9 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Mar 31, 2025, 3:45 PM EDT - 9 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 18, 2025, 8:45 AM EDT - 10 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 13, 2025, 9:00 AM EDT - 10 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

May 22, 2024, 1:30 PM EDT - 1 year ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Mar 26, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023, 11:21 AM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023, 10:05 AM EDT - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

HeyHoser Dec. 29 at 8:18 PM

$IBRX and $DWTX ... nice EOY

0 · Reply

Drainomight Dec. 29 at 6:40 PM

$DWTX

0 · Reply

BillionerOfKing Dec. 25 at 6:29 PM

$DWTX Current Stock Price: $4.36

0 · Reply

GrapeGains Dec. 25 at 9:38 AM

$DWTX Capital discipline has become the critical gating factor, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.

0 · Reply

Fkubini2442 Dec. 23 at 7:42 PM

$DWTX

0 · Reply

HeyHoser Dec. 23 at 7:15 PM

$DWTX wow, nice EOY buy opp.

0 · Reply

hammerfall43 Dec. 23 at 5:18 PM

$DWTX 2$

1 · Reply

UgoGreg Dec. 22 at 7:48 PM

$DWTX https://youtu.be/Pga-Rf9NLOY

0 · Reply

mikesterz7 Dec. 22 at 6:13 PM

$DWTX The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement.

1 · Reply

StocktwitsNews Dec. 22 at 6:05 PM

0 · Reply

thedavidsonny Dec. 22 at 5:47 PM

$DWTX OTLK 🔥 🔥 🔥 🔥 🔥 🔥 🔥 COMING

0 · Reply

ByBi Dec. 22 at 5:40 PM

$DWTX Is this delayed results more then a year ??

0 · Reply

elmono Dec. 22 at 5:25 PM

$DWTX pile of dog shit…short into oblivion

1 · Reply

cfvk Dec. 22 at 5:17 PM

$DWTX this 4.8/4.9 area was old support a while back.

0 · Reply

notreload_ai Dec. 22 at 4:54 PM

$DWTX Phase 2b trial results reveal gaps, delayed timelines, and questions about their chemotherapy pain treatment Halneuron. https://notreload.xyz/dogwood-therapeutics-red-flags-in-latest-trial-update/

0 · Reply

JohnTrack Dec. 22 at 4:21 PM

$DWTX Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain https://www.rapidticker.com/news/dwtx-dogwood-therapeutics-announces-positive-interim-251103

1 · Reply

hammerfall43 Dec. 22 at 4:19 PM

$DWTX 2$

1 · Reply